PT-141
Symbol Pt · MW 1025 Da
Melanocortin agonist studied for sexual response and libido.
- Discovered
- 2000
- Half-life
- 3 hours
- Approval
- FDA-approved (Vyleesi)
Quick facts
- Category
- Hormone
- Route
- Injectable
- Molecular weight
- 1025 Da
- Half-life
- 3 hours
- Discovered
- 2000
- Approval status
- FDA-approved (Vyleesi)
Reported effects
- Libido support
- CNS-mediated
- Sexual function
Overview
PT-141, also known as Bremelanotide, is a melanocortin receptor agonist used for sexual desire and arousal-related support. Unlike medications that primarily affect blood flow, PT-141 works through central nervous system pathways involved in sexual response. It is commonly discussed for libido, sexual function, arousal, and hormone-related wellness. Bremelanotide is medically approved for specific cases of hypoactive sexual desire disorder in premenopausal women. Its purpose is to support sexual desire through melanocortin signaling rather than through testosterone replacement or vascular stimulation.
Evidence context
PT-141 evidence summary
Human clinical evidence
PT-141 has an approval context listed in the Peptidic database. Approved use still depends on the specific indication, formulation, labeling, and clinician guidance.
Animal, preclinical, or formulation evidence
PT-141 may be discussed in animal, preclinical, in vitro, or early-stage research contexts. Those evidence types are useful for orientation but should not be treated as equivalent to approved human indications.
Status and evidence strength
Peptidic lists the approval status for PT-141 as FDA-approved (Vyleesi). The reported effects below are reference fields from the peptide database, not medical promises. Source links are included later on the page when available so readers can continue review from primary or reputable sources.
How it's taken
- Typical Administration
- Injectable
- Typical Dosage
- 1.75 mg
- Typical Frequency
- As needed, at least 45 minutes before anticipated sexual activity; maximum once per 24 hours and no more than 8 doses per month
Dosing depends on the approved indication, formulation, titration schedule, and clinician guidance. This page is educational and not a substitute for medical advice.
Research sources
Source links included from peer-reviewed literature, clinical records, and medical databases for educational research context on PT-141.
Internal links
Related peptides
Frequently asked questions
What category is PT-141 in?
PT-141 is listed in the Hormone category on Peptidic.
What route is PT-141 associated with?
PT-141 is associated with the injectable route in the Peptidic database. This is descriptive route context, not a use instruction.
Is PT-141 approved?
Peptidic lists the approval status for PT-141 as: FDA-approved (Vyleesi). Approval details can vary by indication and jurisdiction.
Interested in PT-141?
Enter your email and we'll send our recommended peptide vendor for educational research reference.
Review the peptide vendor research checklistEducational reference only · No spam · Unsubscribe anytime
For educational purposes only. Many peptides shown are research compounds and not approved for human use in all jurisdictions. Explore the full peptide database, peptide calculator, or peptide tracker.
Last reviewed for educational accuracy: 2026-06-01